P520: PHASE 1/2 STUDY OF SEL24/MEN1703, A FIRST‐IN‐CLASS DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH IDH1/2‐MUTATED ACUTE MYELOID LEUKEMIA: THE DIAMOND‐01 TRIAL

Saved in:
Bibliographic Details
Published inHemaSphere Vol. 6; pp. 419 - 420
Main Authors Martinelli, G., Santoro, A., Gambacorti‐Passerini, C., Vives Polo, S., Solomon, S. R., Mukherjee, S., Lech‐Maranda, E., Yair Levy, M., Wierzbowska, A., Calbacho‐Robles, M., Marconi, G., Benedetta Giannini, M., Cano, I., Torres Miñana, L., Acuña‐Cruz, E., Angelosanto, N., Galleu, A., Baldini, S., Blotta, S., Ravandi, F., Montesinos, P.
Format Journal Article
LanguageEnglish
Published Philadelphia, PA Lippincott Williams & Wilkins 01.06.2022
Wiley
Online AccessGet full text

Cover

More Information
ISSN:2572-9241
2572-9241
DOI:10.1097/01.HS9.0000844968.45342.3d